Cipla Q2 Results: Net profit rises 15.2% YoY to ₹1,303 crore, revenue up 10.5%
- Cipla Q2 Results: Cipla Ltd reported a 15.2% year-on-year increase in consolidated net profit to ₹1,303.53 crore for Q2FY25, with revenue at ₹7,051.02 crore, a 10.5% rise. The North America segment grew 4% to $237 million, while consumer health soared 21% YoY.
Pharma major Cipla Ltd on Tuesday reported an 15.2% year-on-year rise in its consolidated net profit for the fiscal's second quarter ended September (Q2FY25) to ₹1,303.53 crore. The company had reported a profit of ₹1,177.64 crore in the year-ago period. Sequentially, the consolidated net profit was up 10.6%.
Cipla's consolidated revenue from operations stood at ₹7,051.02 crores during the quarter ended September from ₹6,678.15 crore in Q2FY24, a year-on-year jump of nearly 10.5%.
The firm announced an EBITDA increase of 11.6% compared to the same quarter last year, totalling ₹1,886 crore.
At 14:38 IST, post the Q2 results, Cipla share price was trading 2.06% lower at ₹1,472.60 apiece on BSE. According to Rajesh Bhosale, Equity Technical and Derivative Analyst at Angel One, Cipla share prices are hovering around its 200sma placed around 1,470, this is a make or break level, if prices slips further and closes below 1,470 then we may see further weakness towards 1,400 on the flip side, above 1,500 the prices may resume uptrend towards 1,535.
The company's exchange filing revealed a 5% year-on-year growth in One India Business. The Branded Prescription sector continued to surpass market performance in major Chronic therapies. The North America segment reported quarterly revenues of $237 million, reflecting a 4% year-on-year increase, aided by growth in its differentiated portfolio. The company's net cash reserves stand at ₹7,950 crore, with debt mainly consisting of lease obligations and working capital needs.
"In Q2 FY25, we recorded a revenue growth of 9% over last year with a highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies. Our One-India business was impacted during the quarter due to changed seasonal pattern, however key chronic therapies in Branded Prescription business continued to grow faster than the market. Consumer health business grew at a strong 21% YoY.
With our concentrated focus in differentiated portfolio, the US business posted a revenue of $ 237 Mn. In South Africa, we recorded a solid growth of 22% YoY in local currency terms, led by Private Market. Emerging Markets and Europe delivered a robust revenue growth of 18% YoY on the back of deep market focus strategy. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," said Umang Vohra, MD and Global CEO, Cipla Ltd.
Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
- Top Gainers
- Top Losers
- 52 Week High